← All trials
NCT05431075
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2022
- Primary completion
- Aug 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Jun 24, 2022
- Last posted
- Jul 1, 2022
- Enrollment
- 407
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong UniversityLead sponsor
- Peking UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Shandong UniversityOverall official - principal investigator
- Shandong UniversityReponsible party - principal investigator
- Central Hospital, ZiboCollaborator
- Yuncheng Hospital of Traditional Chinese MedicineCollaborator
- Taierzhuang District People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.